Sept 18 (Reuters) - Millennium Pharmaceuticals Inc (MLNM.O: Quote, Profile, Research) said data from a late-stage trial of cancer drug Velcade, in combination with certain other cancer treatments, for the treatment of multiple myeloma, showed statistically significant improvement in all efficacy measures.
In a statement, Millennium said the control arm of the trial was stopped early to allow patients still being treated with the other cancer treatments, melphalan and prednisone, to have Velcade added to their therapy.
Millennium is co-developing Velcade with a unit of Johnson & Johnson (JNJ.N: Quote, Profile, Research). (Reporting by Deepti Chaudhary in Bangalore)
Source: Reuters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment